Avoro Capital Advisors LLC
Institutional investor · Portfolio as of Q4 2020
Top Holdings44 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
MIRATI THERAPEUTICS INC | 4.5M | $996.1M | 17.2% | — | — | 8 qtrssince 2019-Q1 | Increased 66 |
HORIZON THERAPEUTICS PLC | 9M | $658.4M | 11.3% | — | — | 7 qtrssince 2019-Q2 | Increased 73 |
UNITED THERAPEUTICS CORP | 2.9M | $432.6M | 7.5% | $148.68 | 0.00% | 1 qtr | New 97 |
IOVANCE BIOTHERAPEUTICS INC | 7.5M | $348M | 6.0% | $12.44 | +291.82% | 8 qtrssince 2019-Q1 | Decreased 0 |
ARENA PHARMECEUTICALS INC | 4.2M | $321.9M | 5.5% | — | — | 3 qtrssince 2020-Q2 | Increased 79 |
ASCENDIS PHARMA A/S | 1.8M | $300.2M | 5.2% | $118.44 | +43.69% | 8 qtrssince 2019-Q1 | Unchanged 0 |
AVI BIOPHARMA INC | 1.8M | $298.4M | 5.1% | $121.21 | +41.52% | 8 qtrssince 2019-Q1 | Increased 64 |
ARGENX SE - ADR | 902,500 | $265.4M | 4.6% | $132.11 | +125.28% | 8 qtrssince 2019-Q1 | Unchanged 0 |
AMICUS THERAPEUTICS INC | 9M | $207.8M | 3.6% | $12.98 | +76.70% | 8 qtrssince 2019-Q1 | Decreased 0 |
ACCELERON PHARMA INC | 1.6M | $198.3M | 3.4% | — | — | 4 qtrssince 2020-Q1 | Increased 65 |
MERSANA THERAPEUTICS INC | 6.8M | $180.9M | 3.1% | $553.14 | +20.13% | 3 qtrssince 2020-Q2 | Unchanged 0 |
BIOMARIN PHARMACEUTICAL INC | 1.7M | $144.7M | 2.5% | $84.82 | +2.52% | 8 qtrssince 2019-Q1 | Decreased 0 |
MADRIGAL PHARMACEUTICALS INC | 1.2M | $136.2M | 2.3% | $117.90 | -5.75% | 8 qtrssince 2019-Q1 | Increased 69 |
KURA ONCOLOGY INC | 4M | $130.6M | 2.2% | $28.23 | +20.40% | 3 qtrssince 2020-Q2 | Increased 76 |
PMV PHARMACEUTICALS INC | 2.4M | $130.5M | 2.2% | $41.92 | +34.60% | 2 qtrssince 2020-Q3 | Increased 65 |
ACADIA Pharmaceuticals Inc. | 2M | $104.2M | 1.8% | $53.69 | 0.00% | 1 qtr | New 69 |
ADVERUM BIOTECHNOLOGIES INC | 8M | $86.7M | 1.5% | — | — | — | — |
Defiance Trillion Dollar Club I | 5.8M | $85.3M | 1.5% | — | — | 4 qtrssince 2020-Q1 | Increased 51 |
CONSTELLATION PHARMCETICLS I | 3M | $85M | 1.5% | — | — | 5 qtrssince 2019-Q4 | Decreased 0 |
DECIPHERA PHARMACEUTICALS IN | 1.3M | $74.2M | 1.3% | — | — | 5 qtrssince 2019-Q4 | Decreased 0 |
Avoro Capital Advisors LLC manages $5.8B across 44 positions as of Q4 2020. Top holdings: MRTX (17.2%), HZNP (11.3%), UTHR (7.5%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 1.5/5.0.
Active quarter - 7 new positions, 10 exits, 13 increased. Top move: UTHR (NEW, conviction 97). Portfolio: $5.8B across 44 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer